Skip to main content

Table 1 Characteristics at diagnosis of 109 patients with NB

From: BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma

Characteristic

Total

High BPTF

Low BPTF

χ2

P-values

Percent of sample, n (%)

 

55 (50.5)

54 (49.5)

  

Sex, n (%)

   

3.305

0.069

 Male

53 (48.6)

22 (40.0)

31 (57.4)

  

 Female

56 (51.4)

33 (60.0)

23 (42.6)

  

Age (months), n (%)

   

1.155

0.283

  < 18

18 (16.5)

7 (12.7)

11 (20.4)

  

  ≥ 18

91 (83.5)

48 (87.3)

43 (79.6)

  

Staging, n (%)

   

6.694

0.010*

 I-III/IVs

55 (50.5)

21 (38.2)

34 (63.0)

  

 IV

54 (49.5)

34 (61.8)

20 (37.0)

  

Risk group, n (%)

   

5.731

0.017*

 LR or IR

54 (49.5)

21 (38.2)

33 (61.1)

  

 HR

55 (50.5)

34 (61.8)

21 (38.9)

  

MYCN status, n (%)

   

0.057

0.810

 Amplification

15 (13.8)

8 (14.5)

7 (13.0)

  

 Not amplification

94 (86.2)

47 (85.5)

47 (87.0)

  

1p36 status, n (%)

   

0.052

0.819

 LOH

25 (23.6)

13 (24.5)

12 (22.6)

  

 No loss

81 (76.4)

40 (75.5)

41 (77.4)

  

11q23 status, n(%)

   

2.771

0.096

 LOH

34 (32.1)

21 (39.6)

13 (24.5)

  

 No loss

72 (67.9)

32 (60.4)

40 (75.5)

  

PHOX2B, n (%)

   

3.303

0.069

  = 0

51 (46.8)

21 (38.2)

30 (55.6)

  

  > 0

58 (53.2)

34 (61.8)

24 (44.4)

  

LDH (U/L), n (%)

   

1.216

0.749

  ≤ 295

36 (33.0)

18 (32.7)

18 (33.4)

  

 295–500

24 (22.0)

10 (18.2)

14 (25.9)

  

 500–1500

32 (29.4)

18 (32.7)

14 (25.9)

  

  > 1500

17 (15.6)

9 (16.4)

8 (14.8)

  

NSE (ng/l), n (%)

   

4.863

0.088

  ≤ 25

26 (23.9)

12 (21.8)

14 (25.9)

  

 25–100

24 (22.0)

8 (14.5)

16 (29.7)

  

  > 100

59 (54.1)

35 (63.7)

24 (44.4)

  

Primary tumor site, n (%)

   

6.161

0.013*

 Retroperitoneum and adrenal glands

71 (65.1)

42 (76.4)

29 (53.7)

  

 Mediastinum/Pelvic cavity/Neck

38 (34.9)

13 (23.6)

25 ((46.3)

  

Tumor size (cm), n (%)

   

6.262

0.044*

  ≤ 5

26 (23.9)

9 (16.4)

17 (31.5)

  

 5–10

43 (39.4)

20 (36.4)

23 (42.6)

  

  > 10

40 (36.7)

26 (47.2)

14 (25.9)

  

Number of organs with metastasis, n (%)

   

2.711

0.100

  ≤ 3

60 (55.0)

26 (47.3)

34 (63.0)

  

  > 3

49 (45.0)

29 (52.7)

20 (37.0)

  

BM metastasis, n (%)

     

 Yes

49 (45.0)

30 (54.5)

19 (35.2)

4.127

0.042*

 No

60 (55.0)

25 (45.5)

3535353564.8)

  
  1. LR Low-risk, IR Intermediate-risk, HR High-risk, MYCN amplification of the MYCN gene, LDH Lactate dehydrogenase, NSE Neuron-specific enolase, LOH Loss of heterozygosity, BM Bone marrow. * P < 0.05, as assessed by Chi-square test